Alexion Pharmaceuticals Inc. (ALXN)

120.80
2.46 2.00
NASDAQ : Health Technology
Prev Close 123.26
Open 124.12
Day Low/High 120.77 / 124.20
52 Wk Low/High 92.56 / 141.86
Volume 1.52M
Avg Volume 1.42M
Exchange NASDAQ
Shares Outstanding 224.24M
Market Cap 27.67B
EPS 0.30
P/E Ratio 13.10
Div & Yield N.A. (N.A)
Alexion Reports Fourth Quarter And Full Year 2018 Results

Alexion Reports Fourth Quarter And Full Year 2018 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2018.

Alexion To Highlight Rare Disease Portfolio At Investor Day

Alexion To Highlight Rare Disease Portfolio At Investor Day

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that the Company will host an Investor Day on Wednesday, March 20, from 8:00am to 12:30pm ET.

Alexion And Caelum Biosciences Announce Collaboration To Develop Targeted Therapy For Light Chain (AL) Amyloidosis

Alexion And Caelum Biosciences Announce Collaboration To Develop Targeted Therapy For Light Chain (AL) Amyloidosis

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Caelum Biosciences today announced a collaboration to develop CAEL-101 for light chain (AL) amyloidosis.

Alexion Announces Positive Top-Line Results From Phase 3 Study Of ULTOMIRIS™ (Ravulizumab-cwvz) In Complement Inhibitor-Naïve Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Announces Positive Top-Line Results From Phase 3 Study Of ULTOMIRIS™ (Ravulizumab-cwvz) In Complement Inhibitor-Naïve Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Phase 3 study of ULTOMIRIS™ (ravulizumab-cwvz), the company's long-acting C5 complement inhibitor, met its primary objective in complement inhibitor-naïve patients with atypical...

Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019

Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019

It has been a better year for the Russell 2000 and the small-caps it represents.

Alexion To Report Fourth Quarter And Full Year 2018 Results On Monday, February 4, 2019

Alexion To Report Fourth Quarter And Full Year 2018 Results On Monday, February 4, 2019

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2018 before the US financial markets open on February 4, 2019.

Alexion To Present At The 37th Annual J.P. Morgan Healthcare Conference

Alexion To Present At The 37th Annual J.P. Morgan Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 37 th Annual J.

New Year's Investing Resolutions

New Year's Investing Resolutions

The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.

Alexion To Present At The Goldman Sachs 11th Annual Healthcare CEO Conference

Alexion To Present At The Goldman Sachs 11th Annual Healthcare CEO Conference

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the Goldman Sachs 11th Annual Healthcare CEO Conference in New York, NY on Thursday, January 3, 2019 at 8 a.

(Photo: Business Wire)

(Photo: Business Wire)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.

Comprehensive Positive Phase 3 Data For Alexion's ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria Presented At American Society Of Hematology (ASH) Annual Meeting And Published In Blood

Comprehensive Positive Phase 3 Data For Alexion's ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria Presented At American Society Of Hematology (ASH) Annual Meeting And Published In Blood

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the presentation of comprehensive positive Phase 3 data for ALXN1210, the company's investigational long-acting C5 complement inhibitor, at the American Society of Hematology (ASH) Annual...

Alexion To Present At The Evercore ISI Healthcare Conference

Alexion To Present At The Evercore ISI Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Evercore ISI's Healthcare Conference in Boston, MA on Tuesday, November 27, 2018 at 8:45 a.

Alexion To Present At Credit Suisse's 27th Annual Healthcare Conference

Alexion To Present At Credit Suisse's 27th Annual Healthcare Conference

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at Credit Suisse's 27 th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:00 a.

Alexion Completes Acquisition Of Syntimmune

Alexion Completes Acquisition Of Syntimmune

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the previously announced acquisition of Syntimmune has been successfully completed.

Alexion Announces Upcoming Data Presentations At American Society Of Hematology Annual Meeting

Alexion Announces Upcoming Data Presentations At American Society Of Hematology Annual Meeting

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that nine abstracts from its complement research and development program have been accepted for presentation at the American Society of Hematology (ASH) Annual Meeting in San Diego, December 1 to...

Alexion Reports Third Quarter 2018 Results

Alexion Reports Third Quarter 2018 Results

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2018.

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna Pharmaceuticals, Inc.

Alexion To Report Third Quarter 2018 Results On Wednesday, October 24, 2018

Alexion To Report Third Quarter 2018 Results On Wednesday, October 24, 2018

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2018 before the US financial markets open on October 24, 2018.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Alexion To Acquire Syntimmune

Alexion To Acquire Syntimmune

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune today announced that they have entered into a definitive agreement for Alexion to acquire Syntimmune, a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal...

Alexion To Present At The Leerink Partners Roundtable Series: Rare Disease & Oncology

Alexion To Present At The Leerink Partners Roundtable Series: Rare Disease & Oncology

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York, NY on Tuesday, October 2, 2018 at 10 a.

Another Day of Rotation, but of a Different Sort

Another Day of Rotation, but of a Different Sort

Big-cap FAANG names and Apple, in particular, were the beneficiaries.

Alexion Announces Successful Phase 3 PREVENT Study Of Soliris® (Eculizumab) In Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Alexion Announces Successful Phase 3 PREVENT Study Of Soliris® (Eculizumab) In Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced positive topline results from the Phase 3 PREVENT study of Soliris ® (eculizumab) in patients with anti-aquaporin-4 (AQP4) auto antibody-positive neuromyelitis optica spectrum disorder (NMOSD).

The New #45 Most Shorted Nasdaq 100 Component: Alexion Pharmaceuticals

The New #45 Most Shorted Nasdaq 100 Component: Alexion Pharmaceuticals

The most recent short interest data has been released for the 08/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Alexion To Present At Morgan Stanley's 16th Annual Global Healthcare Conference

Alexion To Present At Morgan Stanley's 16th Annual Global Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Morgan Stanley's 16 th Annual Global Healthcare Conference in New York, NY on Friday, September 14, 2018 at 11:05 a.

Alexion To Present At Citi's 13th Annual Biotech Conference

Alexion To Present At Citi's 13th Annual Biotech Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Citi's 13 th Annual Biotech Conference in Boston, MA on Thursday, September 6, 2018 at 8:15 a.

FDA Accepts Priority Review Of ALXN1210 As A Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The US

FDA Accepts Priority Review Of ALXN1210 As A Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The US

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.

Alexion Reports Second Quarter 2018 Results

Alexion Reports Second Quarter 2018 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the second quarter of 2018.

Alexion To Report Second Quarter 2018 Results On Thursday, July 26, 2018

Alexion To Report Second Quarter 2018 Results On Thursday, July 26, 2018

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter ended June 30, 2018 before the US financial markets open on July 26, 2018.

Alexion Submits Application For Approval Of ALXN1210 As A Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The European Union (EU)

Alexion Submits Application For Approval Of ALXN1210 As A Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The European Union (EU)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for ALXN1210, the Company's investigational long-acting C5 complement inhibitor, for the treatment...

TheStreet Quant Rating: B (Buy)